Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The past 12 months have brought numerous exciting advances involving AI and related emerging technologies. Let us not fail to take a short last look at some of the more spectacular flops.
Some investment analysts are predicting a more permissive M&A market, deregulation as a catalyst for growth and fiscal policies that stimulate economic activity. And they see AI as a catalyst in the shift.
After Luigi Mangione, the man accused of killing UnitedHealthcare CEO Brian Thompson, was extradited to New York, federal prosecutors unsealed a new set of murder charges.
Citing two sources familiar with the matter, journalists at CBS News said the health system is suspected of violating the Foreign Corrupt Practices Act. No charges have been filed.
When it comes to adopting healthcare AI, large, well-off hospitals are likely to frequently homer while smaller, struggling institutions go down looking. (Baseball analogy in honor of tonight’s Midsummer Classic.)
Morphic's new treatment for inflammatory bowel disease is in Phase II clinical trials and shows promise in improving patient outcomes. Eli Lilly will purchase the company for $57 per share in cash.
Using the technology and making it work for purpose are two different things. And the U.S. leads all countries in terms of full implementation, at 24% (vs. 19% for China).